Business
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary,
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (\"Halozyme\" or the \"Company\") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated (\"Vertex\"). Under the collaboration, Vertex has licensed Halozyme's Hypercon™ technology for use in up to three drug targets. Hypercon™ is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration.\"This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small volume, patient-delivered next‑generation biologics,\" said Helen Torley, President and Chief Executive Officer of Halozyme. \"Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases.\"\"We are pleased to add Halozyme's Hypercon drug delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases,\" said Mark Bunnage, D.Phil., Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals. \"We look forward to exploring the full potential of this technology across our programs of interest.\"Under the terms of the exclusive agreement, Vertex will make a $15 million upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon™ technology.About HalozymeHalozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology com...